Literature DB >> 6343445

Prostacyclin (PGI2).

S C Davies, S J Machin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6343445     DOI： 10.1007/bf01699256

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  11 in total

1.  Prostacyclin in central retinal vein occlusion.

Authors:  H Zygulska-Mach; E Kostka-Trabka; A Nitoń; R J Gryglewski
Journal:  Lancet       Date:  1980-11-15       Impact factor: 79.321

2.  Vascular prostacyclin may be reduced in diabetes in man.

Authors:  M Johnson; H E Harrison; A T Raftery; J B Elder
Journal:  Lancet       Date:  1979-02-10       Impact factor: 79.321

3.  Plasma 6-keto-prostaglandin F1alpha: fact or fiction.

Authors:  M Greaves; F E Preston
Journal:  Thromb Res       Date:  1982-05-01       Impact factor: 3.944

4.  Rationale and proposal for use of prostacyclin in thrombotic thrombocytopenic purpura therapy.

Authors:  D M Cocchetto; L Cook; A E Cato; J E Niedel
Journal:  Semin Thromb Hemost       Date:  1981       Impact factor: 4.180

5.  Prostacyclin administration during cardiopulmonary bypass in man.

Authors:  D B Longmore; J G Bennett; P M Hoyle; M A Smith; A Gregory; T Osivand; W A Jones
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

6.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

7.  Successful therapy of advanced arteriosclerosis obliterans with prostacyclin.

Authors:  A Szczeklik; R Nizankowski; S Skawinski; J Szczeklik; P Gluszko; R J Gryglewski
Journal:  Lancet       Date:  1979-05-26       Impact factor: 79.321

8.  Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?

Authors:  G Remuzzi; R Misiani; D Marchesi; M Livio; G Mecca; G de Gaetano; M B Donati
Journal:  Lancet       Date:  1978-10-21       Impact factor: 79.321

9.  Binding and inactivation of prostacyclin (PGI2) by human erythrocytes.

Authors:  C Willems; H V Stel; W G van Aken; J A van Mourik
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

10.  Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure.

Authors:  A E Gimson; P G Langley; R D Hughes; J Canalese; P J Mellon; R Williams; H F Woods; M J Weston
Journal:  Lancet       Date:  1980-01-26       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.